Short answer
Pfizer Inc (PFE) filed an 8-K current report with the SEC on May 5, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Pfizer reported first-quarter 2026 financial results, providing the latest operating performance update for investors.
Pfizer Inc 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Pfizer reported first-quarter 2026 financial results, providing the latest operating performance update for investors
- Detailed revenue, earnings, guidance and business-unit metrics appear in Exhibit 99 press release
Item EX-99.1 · Exhibit EX-99.1
- Q1 revenue $14.451B, up 5%; operational growth only 2%, with Comirnaty and Paxlovid declines masking 7% underlying growth excluding COVID products
- Launched and acquired products grew 22% operationally, led by Padcev +39%, Nurtec +41%, oncology biosimilars +52%, and Lorbrena +32%
- Adjusted EPS $0.75, down 18%; adjusted cost of sales rose to 23.6% of revenue from 18.9%, pressuring earnings despite lower SI&A spending
- 2026 guidance reaffirmed: revenue $59.5B-$62.5B and adjusted EPS $2.80-$3.00, with approximately $1.5B expected generic and biosimilar headwind
- Vyndamax settlements extend effective U.S. patent expiry to June 1, 2031, supporting relatively stable revenue from 2028 through mid-2031 subject to litigation outcome
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Pfizer Inc 8-K filings
Get the next PFE 8-K as it lands
Follow PFE for push alerts, or ask the research agent what this filing means.